The EU AI in antibody identification market is undergoing a notable surge, driven primarily by rising investments in biotechnology and a stronger focus on personalized medicine. Analysts anticipate important advancements in medicinal antibody development utilizing artificial intelligence, particularly within fields like oncology and immunotherapeut